|
|
|
Current
Position
|
Chair Professor |
|
Education and Experience
|
1. Sc.D., Department of Cancer Biology, Harvard School of Public Health, Boston, MA, USA
2. M.S., Institute of Microbiology and Immunology, National Yang Ming Chiao Tung University (NYCU), Taiwan
3. Professor and chairman, Institute of Public Health, NYCU, Taiwan
4. Professor, Department of Microbiology and Immunology, NYCU
5. Director, Office of Research Centers, NYCU
6. Vice President, Kaohsiung Medical University (KMU)
7. Legislator at large, Legislative Yuan (Nationwide and Overseas Legislator)
8. Professor, Master Program in Clinical Pharmacogenomics and Pharmacoproteomics, College of Pharmacy, Taipei Medical University (TMU)
9. World's Top 2% Scientist, 2022, 2024.
10. Faith, Hope, and Love Chair Professor, Fu Jen Catholic University (FJCU) 2021-2026.
11. 2008 National Science and Technology Council (NSTC) Outstanding Research Award
12. Outstanding alumnus (Academic achievement), National Yang-Ming University, 2009.
13. The 8th National Innovation Award (國家新創獎) in the Academic Research Category by Institute for Biotechnology and Medicine Industry, 2011
14. National Innovation Award - Excelsior Award (國家新創精進獎), 2024.
|
|
Specialty
|
Tumor Virology
Molecular epidemiology
New Drug Development
Genomic Medicine
National Health Insurance Research Database (NHIRD) Analysis
|
|
Research / Course
|
1. Metabolomic and Genomic Studies on Steatohepatitis
2. Novel Drug Development for Hepatocellular Carcinoma (HCC) and Pancreatic Cancers
3. Application of the GNMT Gene in Cardiovascular Health Promotion |
|
|
|
|
|
|
| A. Joual Paper (The following papers are excerpted from a total of 222 SCI-indexed journal articles published by Professor Chen between 1986 and 2026) |
1. Chen YA, Chen DY, Nee YC, Chen CY, Chang TF, Yeh1 WT, Yang MH, Chen YMA, Tang FY, and Chiang EPI. Glycine N-Methyltransferase Modulates Mitochondria-Derived Formate Fluxes and Central Carbon Metabolism during Methotrexate Therapy. Mol Med (2026). https://doi.org/10.1186/s10020-026-01599-x.
2. Fu YS, Ho WY, Chen PC, Lin SY, Liu CJ, Wu DC, Yang MH, Chen YMA, Tyan YC, Huang B. Mouse embryos as In Vivo models for proteomic identification and functional analysis of missing proteins. Anal Biochem. 2026 Aug:715:116138.
3. Lin CL, Li WY, Wu SJ, Chen PMT, Chen AY, Fann CSJ and Chen YMA*. The Usefulness of Metformin and Ganwei for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Ran-domized, Placebo-Controlled Trial. Int J Mol Sci. 2026 Mar 5;27(5):2411.
4. Lin YC, Li WY, Chen YMA*. GNMT and Its Regulatory MicroRNAs as Biomarkers and Therapeutic Targets for Metabolic Dysfunction-Associated Fatty Liver Disease and Hepatocellular Carcinoma. Int J Mol Sci. 2026 Feb 24;27(5):2090.
5. Jen IA, Li WY, Wu SJ, Chen PMT, Liu WL, Yen YF, Fann CSJ, Chen YMA*. Molecular epidemiology and long-term survival analysis of HIV-1/AIDS patients infected with CRF07_BC, CRF01_AE and subtype B in Taiwan. PLoS One. 2025 Jun 3;20(6):e0323250.
6. Fu YS, Ho WY, Lin SY, Chen PC, Lu CY, Lin SY, Liu CJ, Wu DC, Yang MH, Tsai WC, Chen YMA, Tyan YC, Huang B. Using mouse embryo to identify human missing proteins and the downstream signaling pathways. J Proteome Res 2024 (Submitted).
7. Weldemariam AG, Lin SI, Li WY, Yang MH, Medical Research group of Ethiopia, Alemu YA, Sarusi D, Maayan S, Chen YMA, Chuang KP, Tyan YC, Dai CY. Molecular epidemiology of hepatitis B, hepatitis C, and HIV-1 co-infections in Ethiopia: Implications for disease burden and intervention strategies. Acta Tropica, 257: 2024 (107318).
8. Hsieh KH, Chao CH, Cheng YL, Lai YC, Chuang YC, Wang JR, Chang SY, Hung YP; Chen YMA, Liu WL, Chuang WJ, Yeh TM. Enhancement of NETosis by ACE2-cross-reactive anti-SARS-CoV-2 RBD antibodies in patients with COVID-19. J Biomed Sci. 31:39 2024.
9. Marcelo Chen, Jen IA, Li WY and Chen YMA. Cancer incidence and risk among HIV-infected individuals in Taiwan: results from the combination of two nationwide registries. J AIDS Clinic Res 14:06, 2023
10. Li WY, Yin SH, Huang SW, Yang MH, Chen MT, Wu SR, Kevin Welsher, Yang H and Chen YMA*. The Trajectory Patterns of Single HIV-1 Virus-like Particle in Live CD4 Cells: A Real Time Three-dimensional Multi-resolution Microscopy Study Using Encapsulated Nonblinking Giant Quantum Dot. J Microbio Immunol Infec, 56: 257-266, 2023. (SCI)
11. Kuo KL, Chiang CW, Chen YM, Yu CC and Lee TS. Folic Acid Ameliorates Renal Injury in Experimental Obstructive Nephropathy: Role of Glycine N-Methyltransferase. Int J Mol Sci, 24: 6859, 2023.
12. Yang MH, Li WY, Wu CF, Lee YC, Allan Chen YN, Tyan YC, Chen YM*. Reversal of High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease by Metformin Combined with PGG, an Inducer of Glycine N-Methyltransferase. Int J Mol Sci. 3: 23, 2022.
13. Chang CC, Yang MH, Chang SM, Hsieh YJ, Lee CH, Chen YM, Yuan CH, Chen YL, Ho SY, Tyan YC. Clinical significance of olfactory dysfunction in patients of COVID-19. J Chin Med Asso, 84: 682-689, 2021
14. Ho TC, Chen YM, Chan HP, Chang CC, Chuang KP, Lee CH, Yuan CH, Tyan YC, Yang MH. The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2. Vaccines 9: 1163, 2021.
15. Huang SW, Shen MC, Wang WH, Li WY, Wang JH, Tseng CY, Liu PY, Wang LS, Lee YL, Chen YM, Lee CY, Lu PL, Wang SF. High Prevalence of HIV-1 Transmitted Drug Resistance and Factors Associate with Time to Virological Failure and Viral Suppression in Taiwan. Journal of Antimicrobial Chemotherapy, 77(1):185-195, 2021.
16. Huang SW, Urbina AN, Chen YM*, Wang SF*. A retrospective survey among SASR-CoV-1 infected healthcare workers after three years post-infection. Pathogens, 10(9):1078, 2021.
17. Ho TC, Chang CC, Chan HP, Huang YF, Chen YM, Chuang KP, Lee CH, Yuan CH, Deng YZ, Yang MH*, Yu-Chang Tyan*. Pulmonary findings of F18-FDG PET/CT images on asymptomatic COVID-19 patients. Pathogens, 10(7):839, 2021.
18. Kant R, Yang MH, Tseng CH, Yen, CH, Li WY, Tyan YC, Chen M, Chen YL*, Chen YM*. Discovery of an orally efficacious MYC inhibitor for liver cancer using GNMT-based high throughput screening system and structure-activity relationship analysis. Journal of Medicinal Chemistry, 64(13):8992-9009, 2021.
19. Yang MH, Chen YM, Tu SC, Chi PL, Chuang KP, Chang CC, Lee CH, Chen YL, Lee CH, Yuan CH, Tyan YC. Utilizing an Animal Model to Identify Brain Neurodegeneration-Related Biomarkers in Aging. Int J Mol Sci, 22: 3278, 2021.
20. Ho TC, Wang YH, Chen YL, Tsai WC, Lee CH, Chuang KP, Chen YM, Yuan CH, Ho SY, Yang MH*, Tyan YC*. Chloroquine and Hydroxychloroquine: Efficacy in the Treatment of the COVID-19. Pathogens 10: 217, 2021.
21. Yang MH, Chen SH, Chen KC, You HP, Wu HY, Chen YM, Huang YF, Huang MY, Yuan CH, Lin PH, Tyan YC. Quantitative analysis of progesterone using isotope dilution matrix-assisted laser desorption ionization-time of flight mass spectrometry as a reference procedure for radioimmunoassay. Clinica Chimica Acta, 512: 106-111, 2021.
22. Chen M, Yang MH, Chang MM, Tyan YC, Chen YM*. Tumor suppressor gene glycine N-methyltransferase and its potential in liver disorders and hepatocellular carcinoma. Toxicol Appl Pharmacol., 378:114607, 2019.
23. Kant R, Yen CH, Lu CK, Lin YC, Li JH, Chen YM*. Identification of 1,2,3,4,6-Penta-O-galloyl-β-d-glucopyranoside as a Glycine N-Methyltransferase Enhancer by High-Throughput Screening of Natural Products Inhibits Hepatocellular Carcinoma. Int J Mol Sci., 17(5):669, 2016.
24. Lyu SY, Su LW, Chen YM*. Effects of education on harm-reduction programmes. Lancet 379: e28-e30, 2012. (Epub ahead of print Aug. 17, 2011)
25. Liao, YJ, Liu SP, Lee CM, Yen CH, Chuang PC, Chen CY; Tsai TF; Huang SF, Lee-Wu Yan-Hwa, Chen YM*. Characterization of a glycine N-methyltransferase gene knockout mouse model for hepatocellular carcinoma. Int. J. Cancer, 124: 816-826, 2009.
26. Chen YM* and Kuo HS. HIV-1 in Taiwan. Lancet, 369: 623-625, 2007. (has been chosen as the Article of the Month, April 2007 by the International Harm Reduction Association).
27. Liu SP, Li YS, Chen YJ, Chiang EP, Li AFY, Lee YH, Tsai TF, Hsiao M, Huang CF, Chen YM* Glycine N-methyltransferase-/- mice develop chronic hepatitis and glycogen storage disease in liver. Hepato., 46: 1413-1425, 2007.
28. Chen SY, Lin JR, Darbha R, Liu TY, Lin CH, Chen YM*. Glycine N-Methyltransferase tumor susceptibility gene in the Benzo(a)pyrene-detoxification pathway. Cancer Res., 64: 3617-3623, 2004.
29. Chen YM*, Chen LY, Wong FH, Lee CM, Chang TJ, Yang-Feng TL. Genomic structure, expression and chromosomal localization of the human glycine N-methyltransferase gene. Genomics, 66: 43-47, 2000.
30. Chen YM*, Shiu J-Y, Tzeng SJ, Li-Sun Shih, Yi-Jen Chen and Lui W-Y. Characterization of the glycine-N-methyltransferase-gene expression in human hepatocellular carcinoma. Int. J. Cancer, 75: 787-793, 1998.
31. Chen YM, Gomez-Lucia E, Okayama A, Tachibana N, Lee TH, Mueller N and Essex M. The antibody profile of early HTLV-I infection. Lancet, 336: 1214-1216, 1990.
32. Chen YM, Lee TH, Wiktor SZ, Shaw GM, Murphy EL, Blattner WA and Essex M. Type-specific antigens for serological discrimination of HTLV-I and II infection. Lancet, 336: 1153-1155, 1990.
|
|
1. Chen YM. To be decided. 2026 Annual Meeting of Taiwan Society for Mitochondrial Research and Medicine & Changhua Christian Hospital 130th Anniversary International Symposium on Mitochondrial Medicine, Taiwan, 31st October, 2026. (Submitted)
2. Chen YM. To be decided. Joint Symposium of the 41st SNP, 26th SFRR-Taiwan, and 2026 TATCM & Symposium on Pharmacy and Traditional Chinese Medicine, Taiwan, 30th October-1st November, 2026. (Submitted)
3. Chen YM, Li WY, Wu SJ, Chen PMT, Chen AY, Fann CSJ, Lin CL. The Usefulness of Metformin and Ganwei for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized, Placebo-Controlled Trial. 38th World Congress of Internal Medicine, Taiwan, 12th-15th November, 2026.
4. Chen YM. 抑癌基因GNMT的功能與基因型在脂肪肝防治的臨床應用，振興醫療財團法人振興醫院臨床試驗中心專題演講，台灣，19th March, 2024.
5. Chen YM. 防癌抗老新思路：如何運用基因醫學及精準醫療發展中醫藥，兩岸中醫藥產業發展論壇，北京, 中國，25th-26th December, 2023.
6. Chen YM. 脂肪肝的成因與治療的最新發展，「預防醫學」健康講座，台灣，19th December, 2023.
7. Chen YM. Perspectives on the genetic susceptibility for HCC. 2023 TLCA Symposium on Precision Medicine of Hepatocellular Carcinoma, 24th December, 2023.
8. Chen YM. 國立陽明交通大學醫學院成立沿革及展望，台灣, 11th November, 2023.
9.Chang FY, Chiu CH, Chao YC, Chen YM, Yen LC. Investigations of the pathogenesis and antibody-dependent enhancement of SARS-CoV-2 infection in vitro and in vivo by using BSL-3 facilities. Annual research reports conference of emerging Infectious disease project, Taiwan, 6th November, 2023.
10. Li WY, Lee YJ, Chao YC, Chang FY, Yen LC, Chen YM. Development of anti-SARS-CoV-2 protein and small molecule drugs. Annual research reports conference of emerging Infectious disease project, Taiwan, 6th November, 2023.
11. Wei SC, Hsu WT, Tsai CH, Chang FY, Chiu CH, Chen YM, Yen LC, Chao YC. Establish platforms using baculovirus for COVID-19 detection, immunological analysis and vaccination. Annual research reports conference of emerging Infectious disease project, Taiwan, 6th November, 2023.
12. Chang FY, Chiu CH, Chao YC, Chen YM, Yen LC. Investigations of the correlations of virulence factors, triggered cytokine storm of SARS-CoV-2, and clinical characteristics of COVID-19 patients. Annual research reports conference of emerging Infectious disease project, Taiwan, 6th November, 2023.
13. Lin TY, Chang FY, Chiu CH, Chao YC, Chen YM, Yen LC. Functional characterize of peripheral blood mononuclear cells in COVID-19 patients and clinical characteristics. Annual research reports conference of emerging Infectious disease project, Taiwan, 6th November, 2023.
14. Chen YM. Therapeutic effects of GNMT Inducers for Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma. AASLD The Liver Meeting, Boston, USA, 10th-14th November, 2023.
15. Chen YM. 愛滋病的 流行病學與預防之道，中華民國專業醫事人員「預防醫學教育人才培訓計劃」學分班，台北，30th April, 2023.
16. Chen YM. GNMT 基因型分析在環境職業醫學上的重要性，中華民國專業醫事人員「預防醫學教育人才培訓計劃」學分班，台北，23th April, 2023.
17. Chen YM. 防癌及抗衰老新思路，中華民國專業醫事人員「預防醫學教育人才培訓計劃」學分班，台北，23th April, 2023.
18. Chen YM. 銀光社會力，翻轉高齡新觀念座談會，台北，8th April, 2023.
19. Chen YM. 脂肪肝 (NASH) 防治的最新發展，台灣預防醫學學會年會暨學術研討會，台北，19th March, 2023.
20. Chen YM. 嚴重特殊傳染性肺炎（COVID-19）防疫作為之回顧與檢討，立法院第10屆第6會期社會福利及衛生環境委員會公聽會，台北，21th December, 2022.
21. Chen YM. 人文關懷善的循環：民間組織在傳染病防治上的重要性，2022 橘色善念國際研討會，新北，10th December, 2022.
22. Chen YM. 防癌抗衰老新思路-我的研究及專利申請經驗，台北市護理師護士會【111年度護理創作競賽】，台北，7th December, 2022.
23. Chen YM. 新冠病毒大流行應對的經驗與啓示以台灣地區爲例，海峽兩岸暨港澳醫學會創新合作論壇，北京，中國，4th December, 2022.（線上）
24. Chen YM.「假新聞麥走」後疫情時代 假新聞病毒樣態與因應–從公衛層面說起，「假新聞麥走」論壇，台北，3th December, 2022.
25. Chang FY, Chiu CH, Chao YC, Chen YM, Yen LC. Investigations of the pathogenesis and antibody-dependent enhancement of SARS-CoV-2 infection in vitro and in vivo by using BSL-3 facilities. Annual research reports conference of emerging Infectious disease project, Taiwan, 12th September, 2022.
26. Li WY, Lee YJ, Chao YC, Chang FY, Yen LC, Chen YM. Development of anti-SARS-CoV-2 protein and small molecule drugs. Annual research reports conference of emerging Infectious disease project, Taiwan, 12th September, 2022.
27. Wei SC, Hsu WT, Tsai CH, Chang FY, Chiu CH, Chen YM, Yen LC, Chao YC. Establish platforms using baculovirus for COVID-19 detection, immunological analysis and vaccination. Annual research reports conference of emerging Infectious disease project, Taiwan, 12th September, 2022.
28. Chang FY, Chiu CH, Chao YC, Chen YM, Yen LC. Investigations of the correlations of virulence factors, triggered cytokine storm of SARS-CoV-2, and clinical characteristics of COVID-19 patients. Annual research reports conference of emerging Infectious disease project, Taiwan, 12th September, 2022.
29. Lin TY, Chang FY, Chiu CH, Chao YC, Chen YM, Yen LC. Functional characterize of peripheral blood mononuclear cells in COVID-19 patients and clinical characteristics. Annual research reports conference of emerging Infectious disease project, Taiwan, 12th September, 2022.
30. Chen YM. Glycine N-methyltransferase: A promising drug screening approach for the treatment of hepatocellular carcinoma. United Conference of Oncology Breakthroughs and Formulations, 2021.
31. Chen YM, Rajni K, Yang MH, Li WY. Glycine N-methyltransferase: A promising drug screening approach for the treatment of hepatocellular carcinoma. 14th Meeting of the Asia Pacific Federation of Pharmacologists (APFP), 2021.
32. Chang FY, Chiu CH, Chao YC, Chen YM, Yen LC. Investigation of the pathogenesis and antibody-dependent enhancement (ADE) of SARS-CoV-2 infection in vitro and in vivo by using BSL-3 facilities. Annual research reports conference of emerging Infectious disease project in Taiwan. 2021.
33. Li WY, Lee YJ, You KT, Wu CC, Chao YC, Chang FY, Yen LC and Chen YM. Development of anti-SARS-CoV-2 protein and small molecule drugs. Annual research reports conference of emerging Infectious disease project in Taiwan. 2021.
34. Wei SC, Tsai CH, Hsu WT, Chang FY, Chiu CH, Chen YM, Yen LC. Establish platforms using baculovirus for COVID-19 detection, immunological analysis, and vaccination. Annual research reports conference of emerging Infectious disease project in Taiwan. 2021
35. Chang FY, Chiu CH, Chao YC, Chen YM, Yen LC. Investigation of the correlations of virulence factors, triggered cytokine storm of SARS-CoV-2, and clinical characteristics of COVID-19 patients. Annual research reports conference of emerging Infectious disease project in Taiwan. 2021
36. Lin TY, Chang FY, Chiu CH, Chao YC, Chen YM, Yen LC. Functional characterize of peripheral blood mononuclear cells in COVID-19 patients and clinical characteristics. Annual research reports conference of emerging Infectious disease project in Taiwan. 2021.Yuan-Ling Hsu, Chi-Chung Wang. The functional characterization of inhibition of DNA binding 4 in human lung adenocarcinoma cells. 台灣基因體暨遺傳學會 2011年轉譯醫學研討會暨論文競賽中興大學惠蓀林場December 16-17, 2011.
|
|
|
|
|
1.National Science and Technology Council: Establishing a Metabolomics-Based Decision Support Platform for the Liver-Muscle Axis: From Early Prediction of Progressive MASH to Precision Interventional Strategies for MASLD-Associated Sarcopenia. (2026/06/01~2030/05/31)
2. Institute of Labor, Occupational Safety And Health, Ministry of Labor: Occupational Exposure and Health Monitoring Survey of Steel Industry Workers. (1142022) (2025/04/24~2025/11/20)
3. National Science and Technology Council: The evaluation of combination usage of GNMT inducers and gemcitabine for the treatment of pancreatic cancer via the activation of PTEN pathway. (2023/08/01~2024/07/31)
4. Taiwan Centers for Disease Control: The Plan of Integrated Anonymous Test and Social Network Tracking for Sexually Transmitted Infections. (2023/01/01~2023/12/31)
5. National Science and Technology Council: Evaluation of five novel hepatocellular carcinoma related circulating microRNAs and investigation of their function. (2021/08/01~2023/07/31)
6. National Science and Technology Council: Establishment of Novel Platforms for Immunological Characterization, Drug Screening, and Vaccine Development Against SARS-CoV-2 (2020/11/01~2023/10/31)
|
|
|
|
|
Directed by Professor Yi-Ming Arthur Chen, the Laboratory of Important Infectious Diseases and Cancer is located on the 6th floor of the Paul Cardinal Shan Medical Building, College of Medicine. The laboratory is equipped with advanced instrumentation, including real-time polymerase chain reaction (qPCR) systems, single nucleotide polymorphism (SNP) genotyping platforms, and luminescence microplate readers. Furthermore, our facility houses the only certified Biosafety Level 2 (BSL-2) laboratory within the College of Medicine, facilitating both intra- and inter-institutional collaborative research involving Risk Group 2 (RG2) infectious biological agents.
Our primary research domains encompass both basic and translational medicine. A core research focus involves elucidating the mechanisms of the glycine N-methyltransferase (GNMT) gene in hepatocellular carcinoma (HCC) and hepatic metabolic disorders, alongside developing novel small-molecule therapeutics targeting GNMT for the treatment of HCC and pancreatic cancer. Currently, the laboratory is executing a four-year National Research Program for Metabolomic and Genomic Medicine (2026–2030) funded by the National Science and Technology Council (NSTC). Concurrently, we are formulating GNMT activators derived from combinations of traditional Chinese herbal extracts to investigate their efficacy in anti-aging and the enhancement of exercise performance. Additionally, our research team is dedicated to linking datasets from the Taiwan Biobank and the National Health Insurance Research Database (NHIRD) for comprehensive risk factor analysis. Through these epidemiological efforts, we aim to explore the pathogenic associations between GNMT and other genes involved in the one-carbon metabolism pathway among patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and cohorts occupationally exposed to polycyclic aromatic hydrocarbons (PAHs).
|
|
|
|
|
|
|
|
|
